Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: Regulation and toxicological significance

Journal of Occupational and Environmental Medicine

Volumn 37, Issue 1, 1995, Pages 25-36

  Rannug, Agneta ^a   Alexandria, Anna Karin ^a   Persson, Irene ^b   Ingelman Sundberg, Magnus ^b  

^a NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; CYTOCHROME P450;

CANCER; CANCER RISK; CARCINOGENESIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHENOTYPE; REVIEW; XENOBIOTIC METABOLISM;

ANIMAL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE SUSCEPTIBILITY; EPIDEMIOLOGY, MOLECULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROZYGOTE; HUMAN; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM (GENETICS); SUPPORT, NON-U.S. GOV'T;

EID: 0028963458     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/00043764-199501000-00005     Document Type: Article

References (107)

1. Meyer CF, Zanger UM, Grant D, Blume M. Genetic polymorphism of drug metabolism. Adv Drug Res. 1990; 19:198.
2. Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129-160.
3. Nebert DW. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. In: McClellan RO, ed. The Ah Locus: Genetic Differences in Toxicity, Cancer, Mutation and Birth Defects. Boca Raton: CRC Press; 1989:153-174.
4. Bradfield CA, Bjeldanes LF. Effect of dietary indiole-3-carcinol on intestinal and hepatic monooxygenase, glutathione S-transferase and epoxide hydrolase activities in the rat. J Toxicol Environ Health. 1984;21:311-323.
5. Rannug A, Rannug U. UV-irradiation of tryptophan gives rise to AHH-inducing compounds with very high affinity for the Ah receptor. Chemosphere. 1989;18:1101-1106.
6. Helferich WG, Denison MC. Ultraviolet photoproducts of tryptophan can act as dioxin agonists. Mol Pharmacol. 1991;40:674-678.
7. Kocarek TA, Schuetz EG, Guzelian PS. Transient induction of cytochrome-P450-1 Al messenger RNA by culture medium component in primary cultures of adult rat hepatocytes. In Vitro Cell Dev Biol Anim. 1993;29A:62-66.
8. Mukhtar H, DelTito BJ, Matgouranis PM, et al. Additive effects of ultraviolet B and crude coal tar on cutaneous carcinogen metabolism: possible relevance to the tumorigenicity of the Goeckerman regimen. J Invest Dermatol. 1986; 87:348-353.
9. Goerz G, Merk H, Boise K, et al. Influence of chronic UV-light exposure on hepatic and cutaneous monooxygenases. Experientia. 1983;39:385-386.
10. IARC. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Lyon: International Agency for Research on Cancer, World Health Organization; 1987.
11. Anttila S, Hietanen E, Vainio H, et al. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome-P450IA in lung cancer patients. Int J Cancer. 1991;47:681-685.
12. McLemore TL, Adelberg S, Liu MC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for pulmonary carcinomas. J Natl Cancer Inst. 1990;82:1333-1339.
13. Song BJ, Friedman FK, Park SS, et al. Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science. 1985;228:490-492.
14. Omiecinski CJ, Redlich CA, Costa P. Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res. 1990;50:4315-4321.
15. Vandenheuvel JP, Clark GC, Thompson CL, et al. CYP1A1 Messenger RNA levels as a human exposure biomarker. Use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis. 1993; 14: 2003-2006.
16. Kahn IU, Bickers DR, Haqqi TM, et al. Induction of CYP1A1 mRNA in rat epidermis and cultured human epidermal keratinocytes by benz(a)anthracene and beta-naphthoflavone. Drug Melab Dispos Biol Fate Chem. 1992;20:620-624.
17. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics. 1993;3:213-230.
18. Perdew GH. Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem. 1988;263:13802-13805.
19. r 90,000 heat shock protein. Biochem Biophys Res Commun. 1988; 155:801-807.
20. Hoffman EC, Reyes H, Chu FF, et al. Cloning of a factor required for activity of the Ah (Dioxin) receptor. Science. 1991;252:954-958.
21. Burbach KM, Poland A, Bradfield CA. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA. 1992;89:8185-8189.
22. Ema M, Sogawa K, Watanabe N, et al. cDNA cloning and structure of mouse putative Ah receptor. Biochem Biophys Res Commun. 1992;184:246-253.
23. Gielen JE, Goujon FM, Nebert DW. Genetic regulation of aryl hydrocarbon hydroxylase induction. J Biol Chem. 1972;247:1125-1137.
24. Green MC. Nomenclature of genetically determined biochemical variants in mice. Biochem Genet. 1973;9:369-374.
25. Nebert DW, Gonzalez FJ. P450 genes: structure, evaluatuion and regulation. Annu Rev Biochem. 1987;56:945-993.
26. Harper N, Connor K, Safe S. Immunotoxic potencies of polychlorinated biphenyl (PCB), dibenzofuran (PCDF) and dibenzo-p-dioxin (TCDD) congeners in C57BL/6 and DBA/2 mice. Toxicology. 1993; 11:217-227.
27. Vincek V, Kurimoto I, Medema J, et al. Tumor necrosis factor alpha polymorphism correlates with deleterious effects of ultraviolet B light on cutaneous immunity. Cancer Res. 1993; 53:728-732.
28. Kellermann G, Luyten-Kellermann M, Shaw CR. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet. 1973; 25:327-331.
29. Petruzzelli S, Camus A-M, Carrozzi L, et al. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res 1988;48:4695-4700.
30. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973;289:934-937.
31. Kouri RE, McKinney CE, Slomiany DJ, et al. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982;42:5030-5037.
32. Jaiswal AK, Gonzalez FJ, Nebert DW. Human dioxin-inducible cytochrome P1450: complememtary DNA amino acid sequence. Science. 1985;228:80-83.
33. Hildebrand CE, Gonzalez FJ, McBride OW, et al. Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-dioxin-in-ducible P1450 gene to chromosome 15. Nucleic Acids Res. 1985; 13:2009-2016.
34. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990;263: 131-133.
35. Petersen DD, Mckinney CE, Ikeya K, et al. Human CYPIAI gene—cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48:720-725.
36. Wedlund PJ, Kimura S, Gonzalez FJ, et al. I462V mutation in the human CYPIAI gene: lack of correlation with either the MspI 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. Pharmacogenetics. 1994;4:21-26.
37. Clark G, Tritscher A, Bell D, et al. Integrated approach for evaluating species and interindividual differences in responsiveness to dioxins and structural analogs. Environ Health Perspect. 1992;98:125-132.
38. Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYPIAI gene. J Toxicol Environ Health. 1993;40: 309-316.
39. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed by combined genotypes of P450IA1 and glutathione S-transferase µ-genes. J Basic Clin Physiol Pharmacol. 1992;3(Suppl.):251.
40. Kawajiri K, Nakachi K, Imai K, et al. The CYPIAI gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77-87.
41. 40a. Alexandrie A-K, Ingelman Sundberg M, Seidegård J, Tornling G, Rannug A. Genetic susceptibility to lung cancer: a study of host factors in relation to age at onset and histological cancer types. Carcinogenesis. 1994; 15:1785-1790.
42. 1450) gene: lack of association between the Mspl restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991;1:20-25.
43. Hirvonen A, Husgafvel-Puisiainen K, Karjalainen A, et al. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYPIAI gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992;1:485-489.
44. Shields PG, Sugimura H, Caporaso NE, et al. Polycyclic aromatic hydrocarbon DNA adducts and the CYPIAI restriction fragment length polymorphism. Environ Health Perspect. 1992;98:191-194.
45. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-870.
46. Nakachi K, Imai K, Hayashi SI, et al. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-5180.
47. Johnson BS, Brooks BA, Reyes H, et al. An Msp I RFLP in the human ARNT gene, encoding a subunit of the nuclear form of the Ah (dioxin) receptor. Hum Mol Genet. 1992; 1:351.
48. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes, in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707-715.
49. Geneste O, Camus AM, Castegnaro M, et al. Comparison of pulmonary DNA adduct levels, measured by P-32-postla-belling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis. 1991;12:1301-1305.
50. Bartsch H, Castegnaro M, Rojas M, et al. Expression of pulmonary cytochrome P4501 Al and carcinogen DNA adduct formation in high risk subjects for tobacco-related lung cancer. Toxicol Lett. 1992;64-5:477-483.
51. Shields PG, Bowman ED, Harrington AM, et al. Polycyclic aromatic hydro-carbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 1993;53:3486-3492.
52. 50a. Ichiba M, Hagman L, Rannug A, Hogstedt B, Alexandrie AK, Carstensen U, Hemminki K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYPIAI and GST1 in chimney sweeps. Carcinogenesis. 1994; 15:1347-1352.
53. Rojas M, Camus A-M, Alexandrov K, et al. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis. 1992;13:929-933.
54. Mahgoub A, Dring LG, Idle IR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584.
55. Kalow W, Bertilsson L. In: Testa B, Meyer UA, eds. Advances in Drug Research. London: Academic Press; 1994 25:1-53.
56. Masimirembwa CM, Johansson I, Hasler JA, et al. Genetic polymorphism of cytochrome P4502D6 in Zimbabwean population. Pharmacogenetics. 1993; 3:275-280.
57. 54a. Johansson I, Oscarson M, Yue OY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydrox-ylation. Mol Pharmacol. 1994;46:452-459.
58. Bertilsson L, Åberg-Wistedt A, Gustafs-son LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implifications for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit. 1985; 7:478-480.
59. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P4502D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
60. Ayesh R, Idle JR, Ritchie JC, et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 1984;312:169-170.
61. Crespi CL, Penman BW, Gelboin HV, et al. A tobacco smoke derived nitrosamine 4-(methylnitrosoamino)-1 -(3-pyridyl)-l-butanone is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 1991;12:1197-1202.
62. Cholerton S, Arpanahi A, McCracken N, et al. Poor metabolizers of nicotine and CYP2D6 polymorphism. Lancet 1994;343:62-63.
63. Roots I, Drakoulis N, Ploch M, et al. Debrisoquine hydroxylation phenotype, acetylation phenotype and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr. 1988;66:87-97.
64. Dahl ML, Johansson I, Porsmyr-Palmertz M, et al. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;52:12-17.
65. Broly F, Gaedigk A, Heim M, et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in European population. DNA Cell Biol. 1991;10:545-558.
66. Johansson I, Yue QY, Dahl ML, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol. 1991;40:553-556.
67. Wang SL, Huang J, Lai MD, et al. Molecular basis for genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther. 1993;53:410-418.
68. Evans WE, Relling MV, Rahman A, et al. Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism in black Americans. J Clin Invest. 1993;91:2150-2154.
69. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: concepts, methodolyogy and data review. In: Kalow W, ed. Polymorphic Enzymes and Cancer Risk: Concepts, Methodolyogy and Data Review. New York: Pergamon Press; 1992:825-841.
70. Law RR, Hetzel MR, Idle JR. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer. 1989;59:686-687.
71. Caporaso NE, Tucker MA, Hoover RN, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst. 1990;82:1264-1272.
72. Speirs CJ, Murray S, Davies DS, et al. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol. 1990;29:101-109.
73. Benitez J, Ladero JM, Jara C, et al. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer. 1991;27:158-161.
74. Duche JC, Joanne C, Barre J, et al. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol. 1991;31:533-536.
75. Horsmans Y, Desager JP, Harvengt C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility. Biomed Pharmacother. 1991;45:359-362.
76. Skoda RC, Gonzalez FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P-450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA. 1988;85:5240-5243.
77. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-532.
78. Wolf CR, Smith CAD, Gough AC, et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 1992;13:1035-1038.
79. Tefre T, Daly A, Armstrong M, et al. Genotyping of the CYP2D6 gene in lung cancer patients and controls. J Basic Clin Physiol Pharmacol. 1992; 3(Suppl.):132.
80. Kerb R, Brockmöller J, Drakoulis N, et al. CYP2D6 and glutathione S-transferase class mu as host factors of lung cancer susceptibility. J Basic Clin Physiol Pharmacol. 1992;3(Suppl.):131.
81. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al. PCR-Based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics. 1993;3:19-27.
82. Terelius Y, Lindros KO, Albano E, et al. Isozyme-specificity of cytochrome P450-mediated hepatotoxicity. In: Rein H, Ruckpaul K, eds. Frontiers of Biotransformation, Vol 8. Berlin: Akade-mie Verlag; 1993:187-232.
83. Ronis MJJ, Lindros KO, Ingelman-Sundberg M, et al. The CYP2E family in cytochrome P450. Metabolic and toxicological aspects. Boca Raton: CRC Press; 1994, in press.
84. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P4502E1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol. 1991;4:168-179.
85. Ekström G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P450. Biochem Pharmacol. 1989;38:1313-1319.
86. Koop DR, Kienle E. Stoichiometry of P450 2E1-dependent fatty acid metabolism. ISSX Proc. 1993;4:128.
87. Terelius Y, Ingelman-Sundberg M. Metabolism of n-pentane by ethanol-inducible cytochrome P450 in liver mi-crosomes and reconsituted membranes. Eur J Biochem. 1986;161:303-308.
88. Terelius Y. Cytochrome P450-depend-ent oxygen radical formation and solvent metabolism. PhD thesis, Karolinska Institute, Stockholm, 1991.
89. Johansson I, Eliasson E, Norsten C, et al. Hydroxylation of acetone by ethanol-and acetone-inducible cytochrome P450 in liver microsomes and reconsituted membranes. FEBS Lett. 1986;196:59-64.
90. Johansson I, Lindros KO, Eriksson H, et al. Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Commun. 1990;173:331-338.
91. Badger TM, Huang J, Ronis M, et al. Induction of cytochrome P450 2E1 during chronic ethanol exposure occurs via transcription of the CYP2E1 gene when blood alcohol concentrations are high. Biochem Biophys Res Commun. 1993;190:780-785.
92. Song BJ, Matsunaga T, Hardwick JP, et al. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol. 1987; 1:542-547.
93. Park US, Sohn DH, Song BJ. Transitional activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur J Pharmacol. 1993;248:7-14.
94. Eliasson E, Johansson I, Ingelman-Sundberg M. Ligand-dependent maintenance of ethanol-inducible cytochrome P450 in primary rat hepatocyte cell cultures. Biochem Biophys Res Commun. 1988;150:436-443.
95. Eliasson E, Johansson I, Ingelman-Sundberg M. Substrate, hormone and cAMP-dependent regulation of cytochrome P450 degradation. Proc Natl Acad Sci USA. 1990;87:3225-3229.
96. Song BJ, Veech RL, Park SS, et al. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem. 1989;264:3568-3572.
97. Ronis MJJ, Crough J, Mercado C, et al. Cytochrome P450 CYP2E1 induction during alcohol exposure occurs by a two step mechanism associated with blood alcohol concentrations in rats. J Pharmacol Exp Ther. 1993;264:944-950.
98. McBride OW, Umeno M, Gelboin HV, et al. A Taq I polymorphism in the human P450I1E1 gene on chromosome 10 (CYP2E). Nucleic Acids Res. 1987; 15:10071.
99. Uematsu F, Kikuchi H, Ohmachi T, et al. Two common RFLPs of the human CYP2E gene. Nucleic Acids Res. 1991;19:2803.
100. Uematsu F, Kikuchi H, Motomiya M, et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and suceptibility to lung cancer. Jpn J Cancer Res. 1991;82:254-256.
101. Persson I, Johansson I, Bergling H, et al. Genetic polymorphism of CYP2E1 in a Swedish population. Relationship to the occurrence of lung cancer. FEBS Lett. 1993;319:207-211.
102. Hayashi S-I, Watanabe J, Kawajiri K. Genetic polymorphism in the 5′-flanking region change the transciptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991; 110: 559-565.
103. Watanabe J, Hayashi S-I, Nakachi K, et al. PstI and Rsal RFLPs in complete linkage disequlibrium at the CYP2E gene. Nucleic Acids Res. 1990; 18:7194.
104. Hirvonen A, Husgafvel-Pursiainen K, Anttila S. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis. 1992;14:85-88.
105. Kato S, Shields PG, Caporaso NE, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res. 1992;52:6712-6715.
106. Ingelman-Sundberg M, Johansson I, Hu Y, et al. Ethanol-inducible cytochrome P450 2E1: genetic polymorphism, regulation and possible role in the etiology of alchol-induced liver disease. Alcohol. 1993;10:447-452.
107. Lucas D, Guillermit H, Ferec C, et al. Polymorphisms in the 5′ flanking region of human cytochrome P4502E1 gene in controls and alcoholics. Alcohol Alcoholism. 1993;28:235.